logo

Acceleron Pharma, Inc (XLRN)



Trade XLRN now with
  Date
  Headline
5/19/2021 8:26:07 AM Acceleron Presents Interim Results From Open-label Extension Of PULSAR Phase 2 Trial Of Sotatercept At ATS 2021
5/19/2021 8:18:20 AM Acceleron Pharma Presents Preliminary Interim Data From SPECTRA Phase 2 Trial Of Sotatercept
5/12/2021 11:02:05 AM Acceleron Announces Presentations On REBLOZYL At 2021 European Hematology Association Virtual Congress
4/5/2021 7:14:27 AM Acceleron Announces Clinical Trial Updates, Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension
2/4/2021 7:56:42 AM Acceleron Pharma Expects About $23.0 Mln In Royalty Revenue For Q4
12/14/2020 7:17:04 AM Acceleron Gets Orphan Designation From European Commission For Sotatercept In Pulmonary Arterial Hypertension
12/1/2020 7:09:27 AM Acceleron Receives FDA Orphan Drug Designation For ACE-1334 For Treatment Of Systemic Sclerosis
11/5/2020 7:57:10 AM Acceleron Expects Royalty Revenue Of About $19.3 Mln From Net Sales Of REBLOZYL In Q3
9/29/2020 7:05:12 AM Bristol Myers Squibb Canada And Acceleron Pharma Announce Health Canada Approves REBLOZYL
9/16/2020 7:04:03 AM Acceleron Pharma Appoints Laura Hamill To Its Board
6/24/2020 3:19:43 PM Acceleron Presents Topline Results Of PULSAR Phase 2 Trial Of Sotatercept In Patients With PAH
6/4/2020 4:11:13 PM Acceleron Appoints Christopher Hite To Its Board Of Directors
5/20/2020 7:16:19 AM Acceleron Announces Presentations On REBLOZYL At 2020 ASCO20 Virtual Scientific Program
5/19/2020 7:14:06 AM Acceleron Announces Oral Presentation Of PULSAR Phase 2 Trial Results In Virtual ATS 2020 Conference Session On June 24
5/4/2020 7:05:44 AM Acceleron Pharma: EMA Grants Priority Medicines Designation To Sotatercept
4/8/2020 7:08:23 AM Acceleron Receives FDA Breakthrough Therapy Designation For Sotatercept In Pulmonary Arterial Hypertension